Applicant, as named in the Orange Book
Pf Prism Cv
Pfizer Inc · NYSE: PFE
Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings
Next listed expiry: Pristiq on 5 Jul 2027. 9 products with live protection, 6 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Pristiq NDA 021992 · 3 strengths desvenlafaxine succinate | 5 Jul 2027 patent |
| Xeljanz NDA 203214 · 2 strengths tofacitinib citrate | 21 Aug 2028 exclusivity |
| Xalkori NDA 217581 · 3 strengths crizotinib | 6 Nov 2029 patent |
| Xalkori NDA 202570 · 2 strengths crizotinib | 6 Nov 2029 patent |
| Tygacil NDA 021821 tigecycline | 8 Oct 2030 patent |
| Torisel NDA 022088 temsirolimus | 10 Nov 2032 patent |
| Bosulif NDA 203341 · 3 strengths bosutinib monohydrate | 28 Aug 2034 patent |
| Bosulif NDA 217729 · 2 strengths bosutinib monohydrate | 28 Aug 2034 patent |
| Inlyta NDA 202324 · 2 strengths axitinib | 12 Jul 2037 patent |
Recent events
- Xeljanz · Generic approved · ANDA 218096, ApotexApproved 3 Jun 2026Detected 25 Oct 2026
- Xeljanz · Generic approved · ANDA 219530, Macleods PharmsApproved 3 Jun 2026Detected 25 Oct 2026
- Xeljanz · Generic approved · ANDA 220137, Somerset Theraps LlcApproved 3 Jun 2026Detected 25 Oct 2026
- Xeljanz · Generic approved · ANDA 215552, Yaopharma Co LtdApproved 9 Jun 2026Detected 25 Oct 2026
- Chantix · Generic approved · ANDA 218985, UmedicaApproved 9 Jan 2026Detected 25 Oct 2026
- Vfend · Generic approved · ANDA 220078, Zhejiang NovusApproved 5 May 2026Detected 25 Oct 2026
- Vfend · Generic approved · ANDA 220043, Hainan Poly PharmApproved 14 Nov 2025Detected 25 Oct 2026
- Xeljanz · Generic approved · ANDA 209633, BreckenridgeApproved 3 Jun 2026Detected 25 Oct 2026
- Inlyta · First generic approved · ANDA 211650, ApotexApproved 30 Oct 2025Detected 25 Oct 2026
- Inlyta · Generic approved · ANDA 211650, ApotexApproved 30 Oct 2025Detected 25 Oct 2026
- Xeljanz · Generic approved · ANDA 219395, Specgx LlcApproved 3 Jun 2026Detected 25 Oct 2026
- Chantix · Generic approved · ANDA 219382, Somerset Theraps LlcApproved 6 Jul 2026Detected 25 Oct 2026
- Xeljanz · Generic approved · ANDA 218821, Concord Biotech LtdApproved 9 Jun 2026Detected 25 Oct 2026
- Xeljanz · Generic approved · ANDA 215356, Aurobindo Pharma LtdApproved 3 Jun 2026Detected 25 Oct 2026
- Chantix · Generic approved · ANDA 218302, Micro LabsApproved 29 Oct 2025Detected 25 Oct 2026
- Xeljanz · Generic approved · ANDA 212943, Ajanta Pharma LtdApproved 20 Mar 2026Detected 25 Oct 2026
- Pristiq · Generic approved · ANDA 220460, Yichang HumanwellApproved 10 Mar 2026Detected 25 Oct 2026
- Xeljanz · Generic approved · ANDA 209829, Zydus PharmsApproved 5 Jun 2026Detected 25 Oct 2026
- Inlyta · Generic tentatively approved · ANDA 219705, Sandoz IncTentative approval 7 Oct 2025Detected 25 Oct 2026
- Xeljanz · Generic approved · ANDA 209738, Micro LabsApproved 3 Jun 2026Detected 25 Oct 2026
- Xeljanz · Generic approved · ANDA 217299, MsnApproved 3 Jun 2026Detected 25 Oct 2026
- Pristiq · Enters 12-month window basis: patentListed date 5 Jul 2027Detected 24 Oct 2026
- Pristiq · Enters 12-month window basis: patentListed date 5 Jul 2027Detected 24 Oct 2026
- Pristiq · Enters 12-month window basis: patentListed date 5 Jul 2027Detected 24 Oct 2026
Products without listed protection (6)
| Drug | Earliest generic entry |
|---|---|
| Chantix NDA 021928 · 2 strengths varenicline tartrate | open now no listed protection |
| Rapamune NDA 021110 · 3 strengths sirolimus | open now no listed protection |
| Rapamune NDA 021083 sirolimus | open now no listed protection |
| Vfend NDA 021630 voriconazole | open now no listed protection |
| Vfend NDA 021267 voriconazole | open now no listed protection |
| Vfend NDA 021266 · 2 strengths voriconazole | open now no listed protection |